DWIGHT RAYMOND STICKNEY, M.D.
Radiology at Ashby Ln, Roseville, CA
License number
California C37059
Category
Radiology
Type
Therapeutic Radiology
Address
Address
5275 Ashby Ln, Roseville, CA 95746
Phone
(916) 600-5116
(916) 797-1583 (Fax)
(916) 797-1583 (Fax)
Professional information
Patient Populations And Treatment Methods
US Patent:
2010022, Sep 9, 2010
Filed:
Mar 25, 2010
Appl. No.:
12/732164
Inventors:
Dwight Stickney - Granite Bay CA, US
Christopher L. Reading - San Diego CA, US
James M. Frincke - San Diego CA, US
Christopher L. Reading - San Diego CA, US
James M. Frincke - San Diego CA, US
Assignee:
Harbor BioSciencs, Inc. - San Diego CA
International Classification:
A61K 31/569, A61P 3/10, A61P 9/00, A61P 1/16, A61P 27/02, A61P 3/06
US Classification:
514182
Abstract:
The invention provides 17α-ethynylandrost-5-ene-3β,7β,17β-triol for use in methods to treat, e.g., pre-diabetic hyperglycemia or type 2 diabetes patients having a fasting blood glucose level of at least 110 mg/dL or a post prandial glucose level of at least about 140 mg/dL an optionally a body mass index of >29.9, wherein the patients are not concurrently treated with metformin and optionally another antidiabetic agent. In these methods, the patient will preferably have a fasting insulin level of at least 3.5 to 4 μU/mL.
Drug Screening And Treatment Methods
US Patent:
8217025, Jul 10, 2012
Filed:
Nov 19, 2007
Appl. No.:
11/942664
Inventors:
Jaime Flores-Riveros - Thousand Oaks CA, US
James M. Frincke - Carlsbad CA, US
Christopher Reading - San Diego CA, US
Dwight Stickney - Granite Bay CA, US
Clarence N. Ahlem - San Diego CA, US
James M. Frincke - Carlsbad CA, US
Christopher Reading - San Diego CA, US
Dwight Stickney - Granite Bay CA, US
Clarence N. Ahlem - San Diego CA, US
Assignee:
Harbor Therapeutics, Inc. - San Diego CA
International Classification:
A61K 31/56
US Classification:
514178
Abstract:
The invention relates to methods identify or characterize compounds that can be used to treat specified clinical disorders such as hyperglycemia and type 2 diabetes. Compounds that can be used in these methods include 4α-fluoro-17α-ethynylandrost-5-ene-3β,7β,17β-triol, 4α-fluoro-17α-ethynylandrost-5-ene-3β,7α,17β-triol, 4α-fluoro-17α-ethynylandrost-5-ene-3α,7β,17β-triol and 4α-fluoro-17α-ethynylandrost-5-ene-3β,17β-triol-7-one.
Asthma Treatment Methods
US Patent:
2007026, Nov 15, 2007
Filed:
Oct 16, 2006
Appl. No.:
11/549825
Inventors:
Christopher Reading - San Diego CA, US
Clarence Ahlem - San Diego CA, US
Dominick Auci - San Diego CA, US
Charles Dowding - San Diego CA, US
James Frincke - San Diego CA, US
Mei Li - San Diego CA, US
Theodore Page - Carlsbad CA, US
Dwight Stickney - Granite Bay CA, US
Richard Trauger - Leucadia CA, US
Steven White - San Diego CA, US
Clarence Ahlem - San Diego CA, US
Dominick Auci - San Diego CA, US
Charles Dowding - San Diego CA, US
James Frincke - San Diego CA, US
Mei Li - San Diego CA, US
Theodore Page - Carlsbad CA, US
Dwight Stickney - Granite Bay CA, US
Richard Trauger - Leucadia CA, US
Steven White - San Diego CA, US
International Classification:
A61K 31/56, A61P 11/06
US Classification:
514172000, 514169000
Abstract:
The invention relates to the use of compounds to ameliorate or treat an condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane.
Screening And Treatment Method
US Patent:
2012002, Feb 2, 2012
Filed:
Oct 4, 2011
Appl. No.:
13/252846
Inventors:
Armando Garsd - San Diego CA, US
James M. Frincke - San Diego CA, US
Dwight R. Stickney - Granite Bay CA, US
James M. Frincke - San Diego CA, US
Dwight R. Stickney - Granite Bay CA, US
International Classification:
A61N 5/00
US Classification:
600 1
Abstract:
The invention provides a method to analyze an effect of a biological insult such as exposure to ionizing radiation comprising (a) exposing one or more groups of subjects to a biological insult of at least about an LDto obtain one or more groups of exposed subjects; and (b) measuring one, two, three or more surrogate markers in one or more of the groups of exposed subjects, wherein one, two, three or more of the surrogate markers correlate with death at a P≦0.1.
Therapeutic Treatment Methods
US Patent:
2007027, Nov 29, 2007
Filed:
Feb 12, 2007
Appl. No.:
11/674126
Inventors:
Christopher Reading - San Diego CA, US
Clarence Ahlem - San Diego CA, US
Dominick Auci - San Diego CA, US
Charles Dowding - San Diego CA, US
James Frincke - San Diego CA, US
Mei Li - San Diego CA, US
Theodore Page - Carlsbad CA, US
Dwight Stickney - Granite Bay CA, US
Richard Trauger - Leucadia CA, US
Steven White - San Diego CA, US
Clarence Ahlem - San Diego CA, US
Dominick Auci - San Diego CA, US
Charles Dowding - San Diego CA, US
James Frincke - San Diego CA, US
Mei Li - San Diego CA, US
Theodore Page - Carlsbad CA, US
Dwight Stickney - Granite Bay CA, US
Richard Trauger - Leucadia CA, US
Steven White - San Diego CA, US
International Classification:
A61K 31/58, A61P 19/02, A61K 31/56
US Classification:
514169000, 514178000, 514176000
Abstract:
The invention relates to the use of compounds to ameliorate or treat a condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane.
Therapeutic Treatment Methods
US Patent:
7547687, Jun 16, 2009
Filed:
Feb 12, 2007
Appl. No.:
11/674128
Inventors:
Christopher L. Reading - San Diego CA, US
Clarence N. Ahlem - San Diego CA, US
Dominick L. Auci - San Diego CA, US
Charles Dowding - San Diego CA, US
James M. Frincke - Carlsbad CA, US
Mei Li - San Diego CA, US
Theodore M. Page - Carlsbad CA, US
Dwight R. Stickney - Granite Bay CA, US
Richard J. Trauger - Leucadia CA, US
Steven K. White - San Diego CA, US
Clarence N. Ahlem - San Diego CA, US
Dominick L. Auci - San Diego CA, US
Charles Dowding - San Diego CA, US
James M. Frincke - Carlsbad CA, US
Mei Li - San Diego CA, US
Theodore M. Page - Carlsbad CA, US
Dwight R. Stickney - Granite Bay CA, US
Richard J. Trauger - Leucadia CA, US
Steven K. White - San Diego CA, US
Assignee:
Hollis-Eden Pharmaceuticals, Inc. - San Diego CA
International Classification:
A61K 31/568
US Classification:
514169, 514176
Abstract:
The invention relates to the use of compounds to ameliorate or treat a condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane.
Treatment Methods Using Pharmaceutical Solid State Forms
US Patent:
2013033, Dec 19, 2013
Filed:
Jun 17, 2013
Appl. No.:
13/919728
Inventors:
Steven K. White - San Diego CA, US
Dwight Stickney - Granite Bay CA, US
Dwight Stickney - Granite Bay CA, US
International Classification:
A61K 31/569, A61K 31/337
US Classification:
514171, 514182
Abstract:
The invention provides and describes solid state 17α-ethynyl-5α-androstane-3α,17β-diol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17α-ethynyl-5α-androstane-3α,17β-diol include Form III anhydrate and Form I solvate. The invention further relates to solid and suspension formulations containing 17α-ethynyl-5α-androstane-3α,17β-diol in a described solid state form and use of the formulations to treat cancers or precancers such as prostate cancer or breast cancer in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17α-ethynyl-5α-androstane-3α,17β-diol and uses of such formulations in treating the described conditions.
Metabolic Disease Treatments
US Patent:
2008001, Jan 17, 2008
Filed:
Apr 4, 2007
Appl. No.:
11/696637
Inventors:
Christopher Reading - San Diego CA, US
James Frincke - San Diego CA, US
Clarence Ahlem - San Diego CA, US
Dwight Stickney - Granite Bay CA, US
James Frincke - San Diego CA, US
Clarence Ahlem - San Diego CA, US
Dwight Stickney - Granite Bay CA, US
International Classification:
A61K 31/56, A61K 31/566, A61P 17/02, A61P 3/00, A61P 7/00, A61P 9/00
US Classification:
514182000, 514169000
Abstract:
The invention relates to the use of compounds to treat a number of conditions, such as a pre-diabetes condition, type 1 diabetes, type 2 diabetes, hyperglycemia, insulin resistance and glucose intolerance. Compounds that can be used in one or more of the treatment methods include 3β,7β,16α,17β-tetrahydroxyandrost-5-ene, 3α,7β,16α,17β-tetrahydroxyandrost-5-ene, 3β,7β,16α,17β-tetrahydroxyandrost-5-ene, 3β,16α,17β-trihydroxyandrost-5-ene-7-one, 3β,7β,17β-trihydroxy-17α-ethynylandrost-5-ene, 3β,17β-dihydroxy-17α-ethynylandrost-5-ene-7-one and 3β,7α,17β-trihydroxy-17α-ethynylandrost-5-ene.
Disease Treatment Methods
US Patent:
2008008, Apr 10, 2008
Filed:
Oct 13, 2006
Appl. No.:
11/549615
Inventors:
Christopher L. Reading - San Diego CA, US
Clarence N. Ahlem - San Diego CA, US
Dominick L. Auci - Escondido CA, US
Charles Dowding - San Diego CA, US
James M. Frincke - San Diego CA, US
Mei Li - San Diego CA, US
Theodore M. Page - Carlsbad CA, US
Dwight R. Stickney - Granite Bay CA, US
Richard J. Trauger - Leucadia CA, US
Steven K. White - San Diego CA, US
Clarence N. Ahlem - San Diego CA, US
Dominick L. Auci - Escondido CA, US
Charles Dowding - San Diego CA, US
James M. Frincke - San Diego CA, US
Mei Li - San Diego CA, US
Theodore M. Page - Carlsbad CA, US
Dwight R. Stickney - Granite Bay CA, US
Richard J. Trauger - Leucadia CA, US
Steven K. White - San Diego CA, US
Assignee:
Hollis-Eden Pharmaceuticals, Inc. - San Diego CA
International Classification:
A61K 31/58, A61P 17/06, A61P 3/10, A61P 43/00
US Classification:
514176
Abstract:
The invention relates to the use of compounds to ameliorate or treat a condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α, 17β-trihydroxyandrostane.
Cystic Fibrosis Treatment Methods
US Patent:
2008009, Apr 17, 2008
Filed:
Oct 13, 2006
Appl. No.:
11/549580
Inventors:
Christopher L. Reading - San Diego CA, US
Clarence N. Ahlem - San Diego CA, US
Dominick L. Auci - Sand Diego CA, US
Charles Dowding - San Diego CA, US
James M. Frincke - San Diego CA, US
Mei Li - San Diego CA, US
Theodore Page - Carlsbad CA, US
Dwight R. Stickney - Granite Bay CA, US
Richard J. Trauger - Leucadia CA, US
Steven K. White - San Diego CA, US
Clarence N. Ahlem - San Diego CA, US
Dominick L. Auci - Sand Diego CA, US
Charles Dowding - San Diego CA, US
James M. Frincke - San Diego CA, US
Mei Li - San Diego CA, US
Theodore Page - Carlsbad CA, US
Dwight R. Stickney - Granite Bay CA, US
Richard J. Trauger - Leucadia CA, US
Steven K. White - San Diego CA, US
Assignee:
Hollis-Eden Pharmaceuticals, Inc. - San Diego CA
International Classification:
A61K 31/58, A61K 31/56, A61P 43/00
US Classification:
514173, 514169, 514172, 514176
Abstract:
The invention relates to the use of compounds to ameliorate or treat an condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane.